PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35222283-0	2022	Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma.	Metformin	0-9	epidermal growth factor receptor	Homo sapiens	42-74	
35222283-5	2022	The patients were divided into groups according to whether they were taking metformin for the treatment of T2DM, and the expression of EGFR in different groups was compared.	Metformin	76-85	epidermal growth factor receptor	Homo sapiens	135-139	
35222283-9	2022	Results: EGFR expression in T2DM patients with OSCC taking metformin was significantly lower than that in the non-metformin group.	Metformin	59-68	epidermal growth factor receptor	Homo sapiens	9-13	
35222283-11	2022	In patients with recurrent OSCC with normal blood glucose, metformin remarkably reduced the expression of EGFR in recurrent OSCC tissues.	Metformin	59-68	epidermal growth factor receptor	Homo sapiens	106-110	
35222283-12	2022	Conclusion: Metformin may regulate the expression of EGFR in a way that does not rely on lowering blood glucose.	Metformin	12-21	epidermal growth factor receptor	Homo sapiens	53-57